XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2

Long-Term Investments (Details) - Schedule of long-term investment - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Non-marketable Cost Method Investments, net
Sub total	$ 816,160	$ 932,755
Equity Method Investments, net
Total	816,160	932,755
Braingenesis Biotechnology Co., Ltd. [Member]
Non-marketable Cost Method Investments, net
Sub total	6,948	7,941
Genepharm Biotech Corporation [Member]
Non-marketable Cost Method Investments, net
Sub total	21,213	24,244
BioHopeKing Corporation [Member]
Non-marketable Cost Method Investments, net
Sub total	787,999	900,570
BioFirst Corporation [Member]
Equity Method Investments, net
Total
Rgene Corporation [Member]
Equity Method Investments, net
Total

X

- References

No definition available.

+ Details

Name:	abvc_EquityMethodInvestmentsNetAbstract
Namespace Prefix:	abvc_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	abvc_NonMarketableCostMethodInvestmentsNetAbstract
Namespace Prefix:	abvc_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

This item represents the total non marketable cost method investments net included in earnings for the period as a result of selling marketable securities categorized as trading, available-for-sale, or held-to-maturity and any gains or losses realized during the period from the sale of investments accounted for under the cost method of accounting and/or investments that are separately or otherwise not categorized as trading, available-for-sale, or held-to-maturity. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.

+ References

No definition available.

+ Details

Name:	abvc_NonmarketableCostMethodInvestmentsNet
Namespace Prefix:	abvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

+ Details

Name:	us-gaap_EquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: